Liquid biopsy may predict bladder cancer outcomes, new study hopes

NCT ID NCT07581496

Recruiting now Knowledge-focused Sponsor: University Hospital, Basel, Switzerland Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is looking at whether tiny bits of tumor DNA (ctDNA) found in blood or urine can help doctors better understand and predict the course of a high-risk type of bladder cancer called T1G3. About 35 adults with this cancer will provide samples before, during, and after treatment. The goal is to see if ctDNA can tell which patients need more aggressive therapy and which can avoid it, potentially reducing unnecessary surgeries and side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

urinary bladder carcinoma Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLADDER CANCER

Contacts and locations

Locations

Luzerner Kantonsspital
RECRUITING

Lucerne, Switzerland
Universitätsspital Basel
RECRUITING

Basel, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.